Evidence map›Paper›PMID 36872390›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2023

[

Wei Guo, Yuhang Chen, Xiaojiang He, Hao Fu, Jingxiong Huang, Haojun Chen

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. SSTR antagonist [European journal of nuclear medicine and molecular imaging · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Wei Guo *Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen Cancer CenterXiamen, China.
Yuhang Chen *The School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
Xiaojiang HeDepartment of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen Cancer CenterXiamen, China.
Hao FuDepartment of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen Cancer CenterXiamen, China.
Jingxiong HuangDepartment of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen Cancer CenterXiamen, China.
Haojun ChenDepartment of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen Cancer CenterXiamen, China. leochen0821@foxmail.com.ORCID http://orcid.org/0000-0002-9101-8884
Fujian Medical University · CN

Funding

Medical and health guiding project in Xiamen 3502Z20224ZD1001National Natural Science Foundation of China 82071961
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

InsulinomaOrganometallic CompoundsPancreatic NeoplasmsExenatideHumansPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadionuclide Imagingcopper dotatate CU-64ExenatideOrganometallic Compounds

Identifiers

PMID36872390
OpenAlexW4323295029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.